Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Xylem, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Xylem, Inc. trades at $120 (market cap $28.89B). The key difference: Xylem, Inc. is far larger — about 3.6× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Xylem, Inc. pays a 1.42% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | XYL | |
|---|---|---|
Market Cap | $8.04B | $28.89B |
Sector | Health | Industrials |
52-Week High | $339.75 | $152.95 |
52-Week Low | $241.71 | $106.34 |
Enterprise Value | $7.85B | $30.14B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
XYL trades at $121.21, showing minimal daily change. The stock maintains a bullish technical outlook with consistent earnings beats in recent quarters. Revenue grew to $9.04B in 2025 with a net margin of 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. Analyst consensus is mixed with a $153.14 price target suggesting 26% upside from current levels.
XYL offers solid fundamentals with expanding profitability and strong cash flow generation. Key risks include execution of growth initiatives and macroeconomic sensitivity. The stock presents a compelling opportunity for long-term investors seeking exposure to essential water infrastructure, though near-term volatility may persist around earnings announcements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
